On September 6, 2022 Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, reported that the company will participate in-person at the following upcoming investor conferences (Press release, Theseus Pharmaceuticals, SEP 6, 2022, View Source [SID1234619103]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference: H.C. Wainwright 24th Annual Global Investment Conference
Date / Time: Tuesday, September 13th, 2022, 12:00pm ET
Format: Company Presentation

Conference: Morgan Stanley 20th Annual Global Healthcare Conference
Date / Time: Wednesday, September 14th, 2022, 3:30pm ET
Format: Fireside Chat

Conference: Cantor Fitzgerald’s Oncology, Hematology & HemeOnc Conference
Date / Time: Wednesday, September 28th, 2022, 11:30am ET
Format: Panel Discussion

Live webcasts will be available in the Events section of the company’s investor relations website at ir.theseusrx.com and archived for 30 days following the presentations.

Management will also be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Theseus management team should contact their H.C. Wainwright, Morgan Stanley, or Cantor Fitzgerald representatives.